2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2537

Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Abstract Number: 2538

Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
Abstract Number: 2539

SB4 Shows Comparable Short-Term Effectiveness to Its Etanercept Originator As First-Line Biologic Treatment for Patients with Rheumatoid Arthritis in Routine Clinical Care
Abstract Number: 2540

Effect of Buccal Hygiene on the Systemic Activity of Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Abstract Number: 2541

Impact of 12-Weeks of Upadacitinib Treatment on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Dmards
Abstract Number: 2542

Integrated Exposure-Response Analyses for Upadacitinib Efficacy and Effects on Laboratory Parameters in Rheumatoid Arthritis – Analyses of Phase 2b Studies
Abstract Number: 2543

Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Abstract Number: 2544

Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
Abstract Number: 2545

Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
Abstract Number: 2546

The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Abstract Number: 2547

Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Abstract Number: 2548

The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data
Abstract Number: 2549

Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Abstract Number: 2550

Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
Abstract Number: 2551

Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].